CJC-1295 vs MK-677
Different levers on the same axis: CJC-1295 is a long-acting GHRH analog, MK-677 an oral ghrelin mimetic. Only one has been taken to outcome trials.
Short answer
With human clinical data on both sides, CJC-1295 and MK-677 differ mainly in what they are for. CJC-1295 is marketed for muscle and recovery; MK-677 is the choice for readers interested in muscle and sleep. For CJC-1295, single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trials.
CJC-1295
Sustained GH/IGF-1 rise shown in humans — a surrogate marker, not the body-composition outcome it is sold for.
Full CJC-1295 evidence reviewMK-677
Ibutamoren
An oral ghrelin mimetic that reliably lifts GH, IGF-1 and lean mass — but the same trials found no gain in strength or function, plus metabolic and cardiac safety signals.
Full MK-677 evidence reviewCJC-1295 vs MK-677: head to head
- FDA status / approved use
CJC-1295
Not approved for any marketed use; sold as a research-use-only productMK-677
Investigational; never approved or marketed; sold as a research chemical; prohibited in sport- Marketed for
CJC-1295
Muscle, recovery, 'anti-aging'MK-677
Muscle, sleep, 'anti-aging'- Outcome areas
CJC-1295
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespanMK-677
Muscle / strength / lean mass; Sleep; Longevity / lifespan- Evidence grade
CJC-1295
Clinical dataMK-677
Clinical data- How it works
CJC-1295
Long-acting GHRH analog that stimulates growth hormone releaseMK-677
Oral ghrelin mimetic that amplifies the body's own growth hormone release- Route and dosing
CJC-1295
InjectionMK-677
Oral, once daily; trials used 25 mg- Headline human result
CJC-1295
Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trialsMK-677
Fat-free mass rose 1.1 kg vs a 0.5 kg loss on placebo, without strength or function gains, in a 2-year 2008 trial- Strongest evidence
CJC-1295
Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683MK-677
Nass, Ann Intern Med 2008MK-677 evidence reviewPubMed 18981485- Key safety signal
CJC-1295
No long-term human safety data; chronic GH/IGF-1 stimulation raises concernsMK-677
Raises fasting blood sugar and lowers insulin sensitivity; a heart-failure signal stopped one trial- How it is obtained
CJC-1295
Sold gray-market as a research chemical; no approved or legitimately compounded human productMK-677
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| CJC-1295 | MK-677 | |
|---|---|---|
| FDA status / approved use | Not approved for any marketed use; sold as a research-use-only product | Investigational; never approved or marketed; sold as a research chemical; prohibited in sport |
| Marketed for | Muscle, recovery, 'anti-aging' | Muscle, sleep, 'anti-aging' |
| Outcome areas | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan | Muscle / strength / lean mass; Sleep; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Long-acting GHRH analog that stimulates growth hormone release | Oral ghrelin mimetic that amplifies the body's own growth hormone release |
| Route and dosing | Injection | Oral, once daily; trials used 25 mg |
| Headline human result | Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trials | Fat-free mass rose 1.1 kg vs a 0.5 kg loss on placebo, without strength or function gains, in a 2-year 2008 trial |
| Strongest evidence | Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683 | Nass, Ann Intern Med 2008MK-677 evidence reviewPubMed 18981485 |
| Key safety signal | No long-term human safety data; chronic GH/IGF-1 stimulation raises concerns | Raises fasting blood sugar and lowers insulin sensitivity; a heart-failure signal stopped one trial |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
CJC-1295's best human evidence is pharmacodynamic; single injections produced sustained, multi-day elevations in GH and IGF-1 in healthy adults, and that is where its human record stops. MK-677 went further, raising GH, IGF-1 and fat-free mass in controlled trials, but those same trials found no gain in strength or function, no effect on Alzheimer's progression, and a hip-fracture study was stopped early for a heart-failure signal, alongside consistently higher fasting glucose and reduced insulin sensitivity. Neither is approved and both are sold as research material; the two have not been compared in a trial. MK-677 is better evidenced and the evidence is unfavorable; CJC-1295 is simply untested at the outcome level.
CJC-1295 fits if
CJC-1295 fits the reader focused on how a GHRH signal can be sustained across days, provided they accept that no human outcome data sits behind it.
MK-677 fits if
MK-677 is the better-documented compound and the more useful cautionary read, especially for anyone who assumes a reliable IGF-1 rise implies a real-world benefit.
CJC-1295 vs MK-677: common questions
- Is either CJC-1295 or MK-677 FDA-approved?
- No. CJC-1295 is not approved for any marketed use; sold as a research-use-only product. MK-677 is investigational; never approved or marketed; sold as a research chemical; prohibited in sport.
- Which has stronger human evidence, CJC-1295 or MK-677?
- Neither clearly. Both have human clinical data. The key source for CJC-1295 is Teichman, JCEM 2006; for MK-677, it is Nass, Ann Intern Med 2008.
- What are the main safety concerns with CJC-1295 and MK-677?
- CJC-1295 has no long-term human safety data; chronic GH/IGF-1 stimulation raises concerns. MK-677 raises fasting blood sugar and lowers insulin sensitivity; a heart-failure signal stopped one trial.
Key studies behind each
CJC-1295
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. PubMed 19289567
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PubMed 25331030
MK-677
- Nass R, Pezzoli SS, Oliveri MC, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. PubMed 18981485
- Sevigny JJ, Ryan JM, van Dyck CH, et al. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. PubMed 19015485
- Adunsky A, Chandler J, Heyden N, et al. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. PubMed 21067829
- Murphy MG, Plunkett LM, Gertz BJ, et al. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. PubMed 9467534
The full evidence reviews
- Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides
They reliably raise growth hormone, and that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.
Updated October 2026
- MK-677 (ibutamoren): raises the hormones, not (yet) the outcomes
An oral ghrelin mimetic that reliably lifts GH, IGF-1 and lean mass in human trials — but the same trials found no gain in strength, function or cognition, plus real metabolic and cardiac safety signals.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm CJC-1295 & Ipamorelin availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: California Trim ClinicDr. Gillis' Wellness CenterElitePhysiqMDEmbraceRXIron Med RXJune Health